Videos

David H. Ilson, MD, PhD, discusses the main takeaway from the data for phase III TAGS trial reported at the 2019 Gastrointestinal Cancers Symposium.

Hani M. Babiker, MD, shares his advice for community oncologists treating patients with pancreatic cancer.

Treating An Elderly Woman with Chronic Lymphocytic Leukemia

Lori J. Wirth, MD, discussed the findings for a small cohort of patients with anaplastic thyroid cancer treated with an anti-PD-1 antibody.

Matthew Carlson, MD, discusses his take home message for managing symptoms of chemotherapy in patients with gynecologic cancers.

General Cancer

Heather A. Wakelee, MD, discusses the use of osimertinib as a frontline treatment option for patients with <em>EGFR</em>-positive lung cancer.

Elizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.

Ezra Cohen, MD, FRCPSC, FASCO, discusses the most important parts of successfully managing toxicities related to treatment with immunotherapy.

Michael Gieske, MD, discusses how his community center was able to implement a lung cancer screening program.

Raymond Wadlow, MD, discusses interesting data presented for hepatocellular carcinoma at the 2018 Gastrointestinal Cancers Symposium.

Axel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in&nbsp;patients with&nbsp;<em>BRAF</em>V600E-mutant metastatic colorectal cancer.